Rna Diagnostics Inc.

Pre-clinical studies + retrospective and ongoing prospective clinical data shows strong evidence for the clinical effectiveness of the Veridapt DX™ predictive #biomarker. Veridapt DX identifies non-responsive solid tumors in early #breastcancer by monitoring the degree of #RNA (rRNA) disruption in the cells. It predicts with a high degree of certainty (Negative Predictive Value >93%) whether a patient will benefit from a selected therapy. See a list of publications, including the most recent in the JNCI Cancer Spectrum (2023) ⬇ https://lnkd.in/gVTpdnpU Follow us @ Rna Diagnostics Inc. 🛎 for updates on our progress advancing personalized cancer care. #personalizedmedicine #precisionmedicine #oncology #breastcancer #veridaptDX #rnadiagnostics

Phase 2 of the BREVITY international prospective clinical trial is now under way in 7 countries 🌎 to evaluate our predictive #biomarker platform, Veridapt DX™, as a tool to manage early #breastcancer treatment. Phase 1 results findings, published in JNCI Cancer Spectrum, demonstrated Veridapt DX has a strong capability to accurately predict therapy efficacy/outcomes during early treatment (Negative Predictive Value >93%). Learn more about the BREVITY trial: https://lnkd.in/gawg8Usk Follow Rna Diagnostics Inc. 🛎 for updates on BREVITY and our work to advance personalized cancer care. #personalizedmedicine #precisionmedicine #oncology #breastcancer #veridaptDX #rnadiagnostics

Every day counts in the fight against #cancer. That's why we are developing Veridapt DX™ — a potential practice-changing diagnostic test that measures early solid tumor response to neoadjuvant cancer therapy. An amalgam of the words “verify” and “adapt,” Veridapt DX will enable cancer specialists to verify if chemotherapy is working for their patients and adapt treatment accordingly. The predictive #biomarker identifies non-responsive solid tumors by monitoring the degree of #RNA (rRNA) disruption in the cells. It predicts with a high degree of certainty (Negative Predictive Value >93%) whether a patient will benefit from a selected therapy. With Veridapt DX, oncologists will be able to: ☑ Assess the effect of neoadjuvant therapy as early as 5 weeks into treatment. ☑ Escalate or de-escalate therapy based on early tumor response. ☑ Reduce toxic effects and cost of therapies that don’t work as expected. The test is now being evaluated in Phase 2 of the #BREVITY clinical trials underway at 55 cancer centers in seven countries. Follow us for updates 🛎 on our progress advancing personalized cancer care. #personalizedmedicine #precisionmedicine #oncology #breastcancer #veridaptDX #rnadiagnostics

An incredible level of life sciences innovation, talent and energy at The MedTech Conference in Toronto this week. It was an honour to be part of the #TeamOntario delegation — a big thank you to Patricia Cosgrove for making it happen! With AiimSense, Foqus Technologies Inc., HAS-Motion, Intellijoint Surgical Inc., Invest Ontario, Kinarm (BKIN Technologies Ltd.), MEMOTEXT Corporation, Nanovista Inc., Optimal Innovation Group, PreOperative Performance, Skinopathy, Spiderwort Inc., Steadiwear Inc., Synaptive Medical, TeleVU Innovation, ToeFX Inc., Vessl Prosthetics, WeTraq, Xpan Inc. #medtech24 #medtech #lifesciences #InvestInOntario #mtc24 #medtechinmotion #MedTechCon #personalizedmedicine #oncology #veridaptDX

We’ll be at The MedTech Conference Oct. 15-17 with Team Ontario! It's a perfect opportunity to connect with our CEO John Connolly to explore partnerships for our predictive #biomarker technology, Veridapt DX™. Veridapt DX is a molecular diagnostic test for measuring early solid tumor response to neoadjuvant #cancer treatment. Now in clinical trials for validation in breast cancer, Veridapt DX predicts with a high degree of certainty (Negative Predictive Value >93%) if a patient is not benefiting from therapy. Cancer specialists will be able to use this information to escalate or de-escalate therapy for better patient outcomes. Learn more: https://lnkd.in/d9x5RvVt #medtech24 #medtech #lifesciences #InvestInOntario #mtc24 #medtechinmotion #MedTechCon #personalizedmedicine #oncology #veridaptDX #rnadiagnostics

We're excited to share that Rna Diagnostics Inc. has a new website! 🌐 🎉 🙌 The new site provides a wealth of info + resources on our Veridapt DX™ predictive #biomarker platform technology, which measures early solid tumor response to neoadjuvant #cancer treatment. You’ll find: ✅ an overview of the science behind our molecular diagnostic test, which measures the level of ribosomal RNA (rRNA) disruption in solid tumors ✅ the latest on BREVITY, our international prospective #clinicaltrial to validate Veridapt DX as a tool to manage primary breast cancer treatment ✅ bios for our amazing management team, clinical advisors and board of directors ✅ a list of our publications, and more! Check out the website at: https://lnkd.in/gqHNAqNy #medtech #innovation #personalizedmedicine #precisionmedicine #oncology

We're looking forward to #MTC24 in Toronto Oct. 15-17! Here's a little intro to our mission and our technology: Rna Diagnostics Inc. is a clinical stage molecular diagnostics company for personalized cancer therapy management. Our predictive biomarker platform technology, Veridapt DX™, measures early solid tumor response to neoadjuvant cancer treatment. Veridapt DX identifies non-responsive solid tumors by monitoring the degree of RNA (rRNA) disruption in the cells. Once validated, it will enable physicians to escalate or de-escalate therapy, or select an alternative strategy, as early as 5 weeks into a standard 6-month treatment regimen. Veridapt DX is now entering Phase 2 clinical trial in 7 countries. Get in touch to meet up with our CEO John Connolly at The MedTech Conference to learn more. You can also read about our technology here: https://lnkd.in/d9x5RvVt #medtech #innovation #personalizedmedicine #precisionmedicine #oncology

We'll be at #ESMOBreast24 in Berlin, Germany, May 15-17! Get in touch to meet with our CEO John Connolly and VP Clinical Development Sanaa Noubir to learn about our predictive #biomarker technology for evaluating early tumor response to neoadjuvant treatment. The biomarker test, now in clinical trials, identifies non-responsive solid tumors by monitoring the degree of RNA (rRNA) disruption in the cells. This will enable physicians to escalate or de-escalate therapy, or select an alternative strategy, as early as 5 weeks into a standard 6-month treatment regimen. A large-scale clinical trial, the Breast Cancer Response Evaluation for Individualized Therapy (BREVITY), is now under way to validate this tool to manage primary #breastcancer treatment. Phase 1 results, published in JNCI Cancer Spectrum (Oxford University Press), demonstrate strong capability to accurately predict therapy outcomes during early treatment (Negative Predictive Value >93%). Phase 2 is now under way in 7 countries. We welcome inquiries from clinicians interested in collaborative trials to explore the potential for early assessment of treatment for solid tumor cancers. #personalizedmedicine #precisionmedicine #cancercare #oncology